A second global pivotal trial will test iza-bren in the same NSCLC setting where patri-dxd failed.
ApexOnco Front Page
Recent articles
If Pfizer hands back the estrogen receptor degrader, Arvinas will seek a new partner.
A just revealed clinical trial listing shows Ascentage’s BCL-2 inhibitor being compared against an outdated standard of care.
The company takes another project from Taris into phase 3 as it chases a $5bn market.
The decision highlights the fact that Regeneron is still doing dose-finding work for odronextamab.
Results with eftilagimod alpha in first-line head and neck cancer threaten to cloud partnering prospects.
Other projects new to the clinic include Haisco’s USP1 inhibitor and and Avistone’s type II c-MET blocker.
Checkmate-9DW scores a topline win on overall survival, when failure seemed more likely.